Cambridge Oncometrix’s pivotal clinical study to validate a new test for the early detection of prostate cancer has started to recruit patients. The study is led by UCL and is conducted in three hospitals: in London (UCLH), Leeds (NHS Teaching Hospital), and Norwich...

Cambridge Oncometrix has been shortlisted for the South Norfolk Business Awards 2019! The judges acknowledged for the developed a revolutionary non-invasive pre-biopsy diagnostic test that allows for improved prostate cancer risk assessment in primary and secondary...

Cambridge Oncometrix appoints an industry expert and entrepreneur Erwin Wolf as its Chairman of the Board. Mr. Wolf brings decades of experience in leading technology companies and managing acquisition processes and will strengthen the management team. Learn more

Cambridge Oncometrix’s project - a consortium made up of a three leading clinical partners UCLH, NHS Teaching Hospital Leeds and Norwich&Norfolk UHFT - has been awarded a million pounds of NHS funding to help diagnose prostate cancer.Cambridge...